Guaifenesin

A roundup of the most newsworthy healthcare press releases from PR Newswire this week, including a masterclass on menopause, new treatments to cure blindness and the continuing biotech boom in North Carolina. NEW YORK, Dec. 6, 2024 /PRNewswire/ -- With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help healthcare journalists and consumers stay on top of the week's most newsworthy and popular releases, here's a recap of some major stories from the week that shouldn't be missed. The list below includes the headline (with a link to the full text) and an excerpt from each story. Click on the press release headlines to access accompanying multimedia assets that are available for download. Continue Reading PR Newswire Weekly Health Press Release Roundup, Dec. 2-6, 2024. Lilly's Zepbound® (tirzepatide) Superior to Wegovy® (semaglutide) in Head-to-Head Trial Showing an Average Weight Loss of 20.2% vs. 13.7% Eli Lilly and Company announced topline results from the SURMOUNT-5 phase 3b open-label randomized clinical trial. Zepbound® (tirzepatide) provided a 47% greater relative weight loss compared to Wegovy® (semaglutide). Average Health Insurance Premiums Rise 7% in 2025, Marking Four Consecutive Years of Increases In 2025, private health insurance plans will cost an average of $621 per month, or $7,452 per year - rising 7% from 2024 according to a new report from insurance research site ValuePenguin.com. Residents of 42 states will see higher premiums in 2025 - driven by the rising cost of medical care around the country. MasterClass, Women's Health Advocate Halle Berry and Leading Health Experts Come Together for Stigma-Breaking Class on Menopause Members will learn how to manage symptoms, get practical strategies to thrive and hear inspiring stories of personal experiences—including from Respin founder and longtime menopause advocate Halle Berry. Marking World AIDS Day & Giving Tuesday 2024, (RED) Offers a Galaxy of Gifts That Save Lives This Holiday Season The organization, co-founded by Bono and Bobby Shriver to fight the injustices that enable pandemics to thrive, lights up 'The (RED) Holiday Edit Vol. II.' offering myriad ways to ensure preventable and treatable diseases are preventable and treatable for everyone. From cool tech to fashion and grooming, fragrance to rides on two wheels or four, every action you take with (RED) this holiday season helps save lives. Amgen Announces $1 Billion Manufacturing Expansion in North Carolina The $1 billion facility will incorporate cutting-edge technologies and sustainable practices, aligning with Amgen's commitment to environmental stewardship and manufacturing excellence. In tandem with the existing facility, these investments will create 370 new jobs in the region, supporting a robust biomanufacturing hub. University of Colorado Anschutz Medical Campus-Led Team Receives Up to $46 Million to Develop Innovative Treatment to Cure Blindness "Currently, there has never been a successful whole human eye transplant for the restoration of vision," said principal investigator and surgeon-scientist Kia Washington, MD. "We believe the great advancements over the last two decades in technology, transplantation surgery and regenerative medicine now make restoration of vision possible." Movano Health Receives FDA Clearance for EvieMED Ring "This FDA 510(k) clearance marks a major milestone for the Company and expands our reach to pharmaceutical companies, medical device manufacturers and payors looking for a more accurate, consistent and comfortable health monitoring solution that would help improve compliance by fitting easily into patient lifestyles," said John Mastrototaro, President and CEO of Movano Health. ModifyHealth Raises $13.5M in Funding to Expand Food-as-Medicine Solutions The company announced the funding round led by the Dohmen Company Foundation (DCF) through its Dohmen Impact Investment Fund. With a shared vision to eliminate diet-related disease, Dohmen and ModifyHealth are united in their commitment to scaling innovative food-as-medicine solutions that drive meaningful and sustainable health improvement. Reckitt Opens Its Largest OTC Manufacturing Facility in the U.S. The new state-of-the-art factory in Wilson, North Carolina will produce Mucinex® tablets and liquids to meet increased consumer demand for cold and flu symptom relief in the United States. The Skin of Color Society Foundation Approaches Its 10th Anniversary with Record-Setting Outcomes in Key Supported Programs The Skin of Color Society Foundation (SOCSF) reported record-level growth in key programs that it supports, including an array of innovative research, education, mentorship, and advocacy efforts. The SOCSF was established by the Skin of Color Society (SOCS), an international professional dermatologic organization dedicated to achieving health equity and excellence in patient care through research, education, mentorship and advocacy. Samuel L. Jackson, Kimberly Williams-Paisley and Diedrich Bader Join Alzheimer's Association's First-Ever Fundraising Advertising Campaign "Generation Hope" "Alzheimer's disease has taken my grandfather, grandmother, aunts and uncles. Even my mother. Enough is enough," said Samuel L. Jackson, actor and Alzheimer's Association Celebrity Champion. "I'm proud to join the Alzheimer's Association's 'Generation Hope' campaign because the Association is leading the way in finding a cure and promising new treatments, and providing care and support services for families navigating the disease today." ASTHO Unveils Top Five State Public Health Policy Issues to Watch in 2025 "The prevention of infectious diseases as well as maternal and child health will remain a focus for ASTHO in 2025. Additionally, building up the public health workforce and modernizing our data system will be critical for effective future public health responses," says ASTHO CEO Joseph Kanter, MD, MPH. PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program Under the agreement, PTC will receive an upfront payment of $1.0 billion, up to $1.9 billion in development, regulatory and sales milestones, a profit share in the U.S., and double-digit tiered royalties on ex-U.S. sales. For more news like this, check out all of the latest health-related releases from PR Newswire. Do you have a health press release to distribute? Sign up with PR Newswire to share your story with the audiences who matter most. Helping Journalists Stay Up to Date on Industry News These are just a few of the recent press releases that consumers and the media should know about. To be notified of releases relevant to their coverage area, journalists can set up a custom newsfeed with PR Newswire for Journalists. Once they're signed up, reporters, bloggers, and freelancers have access to the following free features: Customization: Users can create customized newsfeeds that will deliver relevant news right to their inbox. Newsfeed results can be targeted by keywords, industry, subject, geography, and more. Photos and Videos: Thousands of multimedia assets are available to download and include in a journalist or blogger's next story. Subject Matter Experts: Journalists will have access to ProfNet, a database of industry experts to connect with as sources or for quotes in their articles. Related Resources: Our journalist- and blogger-focused blog, Beyond Bylines, features regular media news roundups, writing tips, upcoming events, and more. About PR Newswire PR Newswire is the industry's leading press release distribution partner with an unparalleled global reach of more than 440,000 newsrooms, websites, direct feeds, journalists and influencers and is available in more than 170 countries and 40 languages. From our award-winning Content Services offerings, integrated media newsroom and microsite products, Investor Relations suite of services, paid placement and social sharing tools, PR Newswire has a comprehensive catalog of solutions to solve the modern-day challenges PR and communications teams face. For 70 years, PR Newswire has been the preferred destination for brands to share their most important news stories across the world. For questions, contact the team at [email protected]. SOURCE PR Newswire WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

The FDA has proposed a ban on over-the-counter oral decongestant medicines containing the ingredient phenylephrine, potentially affecting some common brands such as Sudafed, NyQuil, Mucinex and Benadryl. Common oral medicines that have been used for decades as decongestants such as Sudafed, NyQuil and Benadryl may soon be cleared from shelves as the FDA has proposed to discontinue the sale of products containing the active ingredient phenylephrine.Following up on a unanimous advisory committee vote last year, the FDA has asked for feedback on its proposal to outlaw the use of phenylephrine as an oral med.In a 16-0 vote, the Nonprescription Drugs Advisory Committee (NDAC) said in September 2023 that phenylephrine is ineffective when taken as a liquid or in a pill. The ingredient does work however when it is delivered as a nasal spray, the panel agreed. There is no concern with the safety of phenylephrine, the FDA said.“Based on our review of available data, and consistent with the advice of the advisory committee, we are taking this next step in the process to propose removing oral phenylephrine because it is not effective as a nasal decongestant,” Patrizia Cavazzoni, M.D., the director of the FDA’s Center for Drug Evaluation and Research (CDER), said in a release.The advisory committee recommendation was based on data that showed that phenylephrine performed no better than placebo in relieving congestion when taken orally. The compound is designed to reduce the swelling of blood vessels, but the NDAC concluded that when it is received by way of the mouth, not enough of the drug reaches the nasal passages.If the agency makes a final determination—after reviewing public comments—that phenylephrine is not effective, it will issue a final order banning its inclusion in oral medicines. The agency said it would provide manufacturers a grace period to either reformulate their drugs or remove them from the market.The Consumer Healthcare Products Association CEO Scott Melville said in a statement that the organization was “disappointed” by the FDA’s proposal and pointed out that it was “at odds with previous FDA decisions and Advisory Committee recommendations.” For decades, people have relied on oral PE to relieve their nasal congestion,” Melville said. “We believe Americans deserve access to safe and effective OTC medicines and the option to choose the products they prefer for self-care.”Products that include the ingredient—roughly 250 of them—generated approximately $1.8 billion in sales in 2022. Some products contain phenylephrine as a single active ingredient. Others include phenylephrine in combination with other agents.Last year, a month after the NDAC made its recommendations, pharmacy giant CVS said that it would no longer sell meds that contain phenylephrine as its only active ingredient. One such product is Kenvue’s Sudafed PE. “Consumers should know that a range of safe and effective drugs and other treatments is available to temporarily relieve congestion symptoms due to allergies or a common cold,” Theresa Michele, M.D., director of the Office of Nonprescription Drug Products in CDER, said. Phenylephrine is one of two oral decongestants available without prescription. Sales of the other, pseudoephedrine, were restricted in 2006 because it can be misused to make methamphetamine. Products with pseudoephedrine are still available OTC but are often behind store counters or locked away, out of the reach of consumers. There also are limitations on how many pills can be purchased during a store visit.The restrictions led to a boom in products containing phenylephrine. But soon after their rise in popularity, the FDA’s scrutiny of phenylephrine began. In 2007, the NDAC came to a similar conclusion on its ineffectiveness. While four subsequent studies showed the ineffectiveness of phenylephrine when taken as a pill, there was enough variability in the results to raise questions about how the studies were conducted.